Inositol for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Inositol for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Inositol is a sugar-like compound the body makes and food supplies, sold as a supplement at gram doses for blood sugar, hormone, and mood concerns. Human evidence is strongest for blood sugar handling, blood pressure, and blood fats, with the clearest gains in people who begin with disturbed readings. In women whose ovulation is disrupted, cycles and hormone balance improve. Mood, anxiety, and sleep evidence is thinner. (Full Review)

Protocol

Standard metabolic protocol
2 g myo-inositol twice daily
One dose morning and one evening, taken continuously; the regimen used in the postmenopausal metabolic syndrome trials and in most PCOS trials.
Standard reproductive protocol
2,000 mg myo-inositol plus 50 mg D-chiro-inositol twice daily
The 40:1 ratio mirroring the physiological plasma ratio, usually with 200 mcg folic acid.
Best time of day
Morning and evening with meals
For metabolic goals. Pre-bed dosing is used for the sleep and anxiety indication.
Time to effect
Hormonal and glycaemic markers
8 to 12 weeks
The shift seen in most trials.
Menstrual regularity
Three to six months
The typical interval reported.
Sleep and anxiety effects
Days to weeks
Where present.

Benefits

Contraindications
  • People taking lithium for bipolar disorder, unless supervised by the prescribing psychiatrist
  • Women undergoing ovarian stimulation or in vitro fertilisation who would take D-chiro-inositol above 600 mg daily
  • People with chronic kidney disease at stage 4 or worse (eGFR below 30 mL/min/1.73 m²)
  • People with a history of recurrent symptomatic hypoglycaemia, including post-bariatric reactive hypoglycaemia
  • Women who are breastfeeding
    •
Key Interactions
  • Insulin and insulin secretagogues (glipizide, glyburide, gliclazide, repaglinide)
  • Antihypertensive drugs (lisinopril, losartan, amlodipine, hydrochlorothiazide)
  • Ovarian stimulation drugs (recombinant FSH, clomifene, letrozole)
  • Levothyroxine
  • Metformin
  • Glucose-lowering supplements (berberine, alpha-lipoic acid, chromium picolinate, cinnamon extract, Gymnema sylvestre)
  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium, potassium, hibiscus, garlic extract)
  • Selenium (at or below 200 mcg daily)
  • Alpha-lactalbumin
  • Caffeine-containing analgesics and stimulants
  • Carbohydrate restriction and endurance training
    •

Risk & Side Effects

  • High: Dose-dependent gastrointestinal intolerance
    •
  • Medium: Deterioration of egg quality with high-dose D-chiro-inositol; excess infections and deaths at high doses of the scyllo-inositol isomer
  • Low: Hypoglycaemia when combined with glucose-lowering therapy; additive blood-pressure lowering; suppression of oestrogen by D-chiro-inositol; interference with lithium's mood-stabilising action
  • Speculative: Accumulation in reduced kidney function
    •

Monitoring

Marker Target Why
Fasting insulin 2–5 µIU/mL The most responsive marker of inositol's core action
HOMA-IR Below 1.0 Combines fasting glucose and insulin into one insulin-resistance index
Fasting glucose 75–86 mg/dL Confirms the glycaemic effect and flags over-lowering
HbA1c 4.8–5.3% The durability check on the glycaemic effect
Triglycerides Below 80 mg/dL The lipid fraction that moves most with inositol
Triglyceride-to-HDL ratio Below 1.5 Single best surrogate for insulin resistance from a standard lipid panel
LDL cholesterol Below 100 mg/dL, lower with risk factors Detects the smaller but statistically consistent lipid effect
Home blood pressure 110–120 / 70–78 mmHg Captures the 5–7 mmHg fall and warns of over-lowering
Thyroid-stimulating hormone 0.5–2.0 µIU/mL Inositol lowers this in autoimmune thyroiditis and can unmask excess levothyroxine
Total testosterone (women) 15–45 ng/dL The androgen endpoint with the strongest trial support
Sex hormone-binding globulin 40–80 nmol/L (women) Rises with inositol and lowers free androgen exposure
Total testosterone (men) 600–900 ng/dL The endpoint for D-chiro-inositol use in men
Oestradiol (men) 20–30 pg/mL Guards against excessive oestrogen suppression from D-chiro-inositol
eGFR No established inositol-specific target exists; track change from the individual's own baseline instead Inositol is renally cleared and untested in reduced kidney function

Cadence: Home blood pressure weekly for the first four weeks, then monthly; the full blood panel repeated at 12 weeks, then every 6 to 12 months. Thyroid function rechecked at 8 to 12 weeks in anyone on levothyroxine; daily glucose self-monitoring covers the first month in anyone on insulin or a sulfonylurea.

Qualitative Assessment

  • Sleep quality and time to fall asleep, ideally scored on the same simple scale weekly rather than recalled
  • Daytime anxious arousal and mental chatter, the effect most often reported at low doses
  • Menstrual cycle length and regularity, the endpoint with the strongest trial support in women
  • Energy stability across the afternoon, a practical proxy for improved glucose handling
  • Grip strength and self-reported sexual function in men using D-chiro-inositol
  • Bloating, flatulence, and stool consistency, the earliest signal that the dose is too high
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.